Cash Flow Statement

Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances

Daily Values

Growth Metrics

Others

EBIAT Leases Long-Term Debt Issuances Long-Term Debt Repayments Other Gross PP&E Adjustments Other Gross PP&E Adjustments Preferred Shares Issued Receivables - Other Shares Issued Shares Outstanding Shares Outstanding Short-Term Debt issuances

Ratios

MoonLake Immunotherapeutics (MLTX) Shares Repurchased (2021 - 2024)

MoonLake Immunotherapeutics' Shares Repurchased history spans 2 years, with the latest figure at $50.0 for Q1 2024.

Quarterly Shares Repurchased changed N/A to $50.0 in Q1 2024 from the year-ago period, while the trailing twelve-month figure was $50.0 through Dec 2024, changed N/A year-over-year, with the annual reading at $50.0 for FY2024, N/A changed from the prior year.
Shares Repurchased came in at $50.0 for Q1 2024, down from $6202.0 in the prior quarter.
In the past five years, Shares Repurchased ranged from a high of $6202.0 in Q4 2021 to a low of $50.0 in Q1 2024.